Loading...
BVMF
BIOM3
Market cap162mUSD
Jun 16, Last price  
6.52BRL
1D
-6.86%
1Q
-35.45%
Jan 2017
5.49%
IPO
462.53%
Name

Biomm SA

Chart & Performance

D1W1MN
BVMF:BIOM3 chart
No data to show
P/E
—
P/S
6.24
EPS
—
Div Yield, %
—
Shrs. gr., 5y
19.51%
Rev. gr., 5y
74.06%
Revenues
143m
+20.91%
6,645,0001,995,0003,017,000608,000877,000000000103,0001,566,0008,944,00058,668,000107,090,000104,954,000118,194,000142,905,000
Net income
-77m
L-4.81%
6,000-5,318,000-7,412,000-7,016,000-4,273,000-4,675,000-14,140,000-10,059,000-12,713,0008,282,000-45,608,000-38,128,000-42,562,000-55,812,000-70,767,000-80,261,000-92,559,000-81,141,000-77,238,000
CFO
-92m
L+22.81%
-5,715,000-5,310,000-4,640,000-1,784,000-7,103,000-10,508,000-19,784,000-13,899,000-38,281,000-54,405,000-44,115,000-80,852,000-96,874,000-93,784,000-62,999,000-74,785,000-91,845,000

Profile

Biomm S.A. operates as a biotechnology company in Brazil. It offers AFREZZA, a human insulin inhalation powder; CONFORT CARE, a moisturizing foot cream; GLARGILIN, a glargine insulin; and HERZUMA, a trastuzumab. Biomm S.A. was founded in 2001 and is based in São Paulo, Brazil.
URL
https://biomm.com/
IPO date
Sep 05, 2002
Employees
Domiciled in
BR
Incorporated in
BR

Valuation

Title
BRL in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
142,905
20.91%
118,194
12.62%
104,954
-1.99%
Cost of revenue
214,696
198,009
178,845
Unusual Expense (Income)
NOPBT
(71,791)
(79,815)
(73,891)
NOPBT Margin
Operating Taxes
644
340
(630)
Tax Rate
NOPAT
(72,435)
(80,155)
(73,261)
Net income
(77,238)
-4.81%
(81,141)
-12.34%
(92,559)
15.32%
Dividends
Dividend yield
Proceeds from repurchase of equity
217,012
45,000
128,326
BB yield
-16.65%
-9.36%
-25.04%
Debt
Debt current
44,503
47,660
51,060
Long-term debt
76,880
105,940
121,224
Deferred revenue
Other long-term liabilities
36,118
32,366
32,302
Net debt
34,461
91,188
83,027
Cash flow
Cash from operating activities
(91,845)
(74,785)
(62,999)
CAPEX
(19,158)
(6,222)
(5,439)
Cash from investing activities
(37,986)
(2,857)
(6,160)
Cash from financing activities
180,874
25,559
113,788
FCF
(87,034)
(64,342)
(77,618)
Balance
Cash
143,440
53,738
80,336
Long term investments
(56,518)
8,674
8,921
Excess cash
79,777
56,502
84,009
Stockholders' equity
246,358
106,584
143,360
Invested Capital
340,508
251,704
279,686
ROIC
ROCE
EV
Common stock shares outstanding
122,234
83,213
75,466
Price
10.66
84.43%
5.78
-14.87%
6.79
-47.69%
Market cap
1,303,014
170.91%
480,971
-6.14%
512,413
-43.65%
EV
1,337,475
572,159
595,440
EBITDA
(59,907)
(68,335)
(61,640)
EV/EBITDA
Interest
11,607
14,954
14,276
Interest/NOPBT